-+ 0.00%
-+ 0.00%
-+ 0.00%

Nuvectis Pharma's NXP200 BRAF Inhibitor Receives China's Breakthrough Therapy Designation

Benzinga·09/24/2026 12:05:49
Listen to the news

Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, announced today that NXP200 (HSK42360), an oral, brain-penetrant, paradox-breaker BRAF inhibitor, has been granted Breakthrough Therapy Designation (BTD) for the treatment of patients with BRAF V600-mutant, recurrent or progressive high-grade glioma by China’s Center for Drug Evaluation (CDE).